Compass-logo-RGB-outlines.png
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
12 avr. 2024 08h00 HE | Compass Therapeutics
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
logo-horizontal-main.png
Oncocyte Reports Full Year 2023 Financial Results
12 avr. 2024 06h00 HE | OncoCyte Corporation
ONCOCYTE REPORTS FULL YEAR 2023 FINANCIAL RESULTS
logo-horizontal-main.png
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
11 avr. 2024 21h46 HE | OncoCyte Corporation
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
logo-horizontal-main.png
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
11 avr. 2024 17h30 HE | OncoCyte Corporation
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
AIMLogo.jpg
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
11 avr. 2024 11h00 HE | AIM ImmunoTech Inc.
OCALA, Fla., April 11, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
Tevogen Logo Notified.png
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
11 avr. 2024 08h05 HE | Tevogen Bio Inc
Tevogen’s Chief Scientific Officer explains the company’s oncology pipeline strategy as it relates to harnessing Cytotoxic T Lymphocytes to target cancers.
New Logo.png
Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting
11 avr. 2024 08h00 HE | Provectus Biopharmaceuticals Inc.
PV-10 demonstrated significant anti-tumor activity in vivo in head and neck cancers KNOXVILLE, TN, April 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the...
arvinas_logoART_lg.jpg
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
11 avr. 2024 07h00 HE | Arvinas Inc.
– Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01...
UCBC logo.png
University Cancer & Blood Center and University Health Alliance open High-Risk GI Clinic to address community needs
10 avr. 2024 11h48 HE | University, Cancer and Blood Center
University Cancer & Blood Center and University Health Alliance open High-Risk GI Clinic to address community needs.
UPMC
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
10 avr. 2024 08h21 HE | AIM ImmunoTech Inc.
OCALA, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda...